Copyright: ©Author(s) 2026.
World J Gastroenterol. Nov 28, 2026; 32(44): 120795
Published online Nov 28, 2026. doi: 10.3748/wjg.120795
Published online Nov 28, 2026. doi: 10.3748/wjg.120795
Table 3 Hazard ratios of recurrence-free survival by pathological stage
| Unadjusted | IPTW-adjusted | ||||
| HR (95%CI) | P value | HR (95%CI) | P value | ||
| pStage I | M-GC | 1.00 | 0.064 | 1.00 | 0.234 |
| EOGC | 0.38 (0.14-1.06) | 0.60 (0.26-1.40) | |||
| pStage II | M-GC | 1.00 | 0.080 | 1.00 | 0.136 |
| EOGC | 0.47 (0.17-1.10) | 0.50 (0.20-1.25) | |||
| pStage III | M-GC | 1.00 | 0.043 | 1.00 | 0.032 |
| EOGC | 0.53 (0.29-0.98) | 0.50 (0.26-0.94) | |||
| Total population | M-GC | 1.00 | 0.014 | 1.00 | 0.021 |
| EOGC | 0.57 (0.36-0.89) | 0.50 (0.38-0.93) | |||
- Citation: Jeong SA, Lee JB, Kim JH. Clinicopathological characteristics and survival outcomes of early-onset vs mid-aged gastric cancer using an evidence-based age cutoff. World J Gastroenterol 2026; 32(44): 120795
- URL: https://www.wjgnet.com/1007-9327/full/v32/i44/120795.htm
- DOI: https://dx.doi.org/10.3748/wjg.120795